Topiroxostat influences circulating lipid concentrations in hyperuricemic patients .
Hyperuricemia is an independent risk factor for renal dysfunction, cardiovascular events, and gouty arthritis. Xanthine oxidoreductase (XOR) inhibitors inhibit uric acid (UA) production and may be treatment options for hyperuricemia patients. I aimed to evaluate the effects of topiroxostat on circulating lipid concentrations in patients with hyperuricemia. 83 hyperuricemic patients taking topiroxostat were enrolled into this retrospective study. Serum UA significantly decreased, total cholesterol (TC) decreased, and low-density lipoprotein cholesterol (LDL-c) decreased between baseline and 24 weeks. Topiroxostat may have the potential to lower serum UA, TC, and LDL-c concentrations in hyperuricemic patients.